Brentuximab vedotin or physician's choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trial

H. Miles Prince, M. D’Incan, Brigitte Dréno et al.|The Lancet|2017

Cited by 580